Xeris Biopharma Holdings Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	91.6	71.62	67.45	121.97	67.27	37.6
Short-Term Investments	-	-	5	-	35.16	96.19
Cash & Short-Term Investments	91.6	71.62	72.45	121.97	102.43	133.79
Cash Growth	31.98%	-1.15%	-40.60%	19.07%	-23.44%	77.09%
Accounts Receivable	53.75	40.42	39.2	30.83	17.46	6.88
Receivables	53.75	40.42	39.2	30.83	17.46	6.88
Inventory	67.46	48.18	38.84	24.74	18.12	8.35
Prepaid Expenses	11.21	7.45	5.78	9.29	4.59	3.2
Total Current Assets	224.02	167.66	156.26	186.82	142.6	152.21
Property, Plant & Equipment	27.21	28.21	29.18	9.51	6.63	6.71
Goodwill	22.86	22.86	22.86	22.86	22.86	-
Other Intangible Assets	90.79	98.92	109.76	120.61	131.45	-
Other Long-Term Assets	5.32	5.41	4.54	4.73	0.83	0.23
Total Assets	370.19	323.06	322.6	344.52	304.36	159.15
Accounts Payable	6.53	2.29	11.57	4.61	8.92	3.12
Accrued Expenses	81.61	56.8	45.66	44.09	51.17	21.07
Current Portion of Long-Term Debt	-	15.1	-	-	-	-
Current Portion of Leases	6.19	6.08	3.5	1.58	-	-
Other Current Liabilities	21.87	20.17	34.47	23.35	18.95	4.02
Total Current Liabilities	116.2	100.44	95.19	73.62	79.04	28.21
Long-Term Debt	219.47	217.01	190.93	187.08	88.07	87.02
Long-Term Leases	31.99	33.26	34.76	9.4	-	-
Long-Term Deferred Tax Liabilities	-	-	2.27	3.52	4.94	-
Other Long-Term Liabilities	3.39	1.97	6.23	25.72	37.08	10.16
Total Liabilities	371.05	352.68	329.38	299.34	209.13	125.39
Common Stock	0.02	0.02	0.01	0.01	0.01	0.01
Additional Paid-In Capital	681.54	642.26	610.25	599.97	555.36	371.13
Retained Earnings	-682.39	-671.86	-617.03	-554.77	-460.11	-337.39
Comprehensive Income & Other	-0.03	-0.03	-0.03	-0.02	-0.03	0.01
Total Common Equity	-0.86	-29.62	-6.78	45.19	95.23	33.76
Shareholders' Equity	-0.86	-29.62	-6.78	45.19	95.23	33.76
Total Liabilities & Equity	370.19	323.06	322.6	344.52	304.36	159.15
Total Debt	257.65	271.45	229.19	198.06	88.07	87.02
Net Cash (Debt)	-166.06	-199.83	-156.74	-76.09	14.37	46.77
Net Cash Growth	-	-	-	-	-69.28%	171.21%
Net Cash Per Share	-1.06	-1.36	-1.14	-0.56	0.18	1.10
Filing Date Shares Outstanding	165.92	153.94	140.45	137.29	135.52	59.76
Total Common Shares Outstanding	165.53	149.43	138.13	136.27	124.87	59.61
Working Capital	107.82	67.22	61.07	113.2	63.56	124.01
Book Value Per Share	-0.01	-0.20	-0.05	0.33	0.76	0.57
Tangible Book Value	-114.51	-151.4	-139.41	-98.28	-59.08	33.76
Tangible Book Value Per Share	-0.69	-1.01	-1.01	-0.72	-0.47	0.57
Machinery	6.58	6.26	5.65	5.68	5.43	4.32
Leasehold Improvements	5.7	6.06	5.98	5.07	5.03	4.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.